Literature DB >> 34907766

Alterations of glycaemia, insulin resistance and body mass index within the C-peptide optimal range in non-diabetic patients.

Vladimir Kron1,2, Miroslav Verner3,4, Pavel Smetana1, Jana Janoutova5, Vladimir Janout6, Karel Martinik2.   

Abstract

The study focused on changes or cut-offs of glycaemia, insulin resistance and body mass index within the C-peptide reference range (260-1730 pmol/l). The metabolic profile of individuals in the Czech Republic without diabetes (n = 3186) was classified by whiskers and quartiles of C-peptide into four groups with the following ranges: 290-510 (n = 694), 511-710 (n = 780), 711-950 (n = 720) and 951-1560 pmol/l (n = 673). Fasting levels of glucose, insulin, HOMA IR (Homeostasis Model Assessment for Insulin Resistance) and BMI (body mass index) were compared by a relevant C-peptide range. Participants taking medication to control glycaemia were excluded. The evaluation involved correlations between C-peptides and the above parameters, F-test and t-test. Changes in glucose levels (from 5.3 to 5.6 mmol/l) between the groups were lower in comparison to insulin, which reached relatively greater changes (from 4.0 to 14.2 mIU/l). HOMA IR increased considerably with growing C-peptide concentrations (0.9, 1.5, 2.2 and 3.5) and BMI values showed a similar trend (28.3, 31.0, 33.6 and 37.4). Considerable changes were observed for insulin (5.2 mIU/l, 57.8%) and HOMA IR (1.3, 61.3%) between groups with C-peptide ranges of 711-950 and 951-1560 pmol/l. Although correlations involving C-peptide, insulin, glucose and BMI seemed to be non-significant (up to rxy = 0.25), the mean values of insulin, HOMA IR and BMI showed statistically significant changes between all groups with various C-peptide concentrations (p ≤ 0.001). Generally, most important differences appeared in glucose metabolism and body mass index between C-peptide ranges of 711-950 and 951-1560 pmol/l. Absolute and relative changes of C-peptide concentrations are possible to use for the assessment of glucose regulatory mechanism. The spectrum of investigated parameters could be a useful tool to prevent the risks linked with the alterations of glycaemia.

Entities:  

Keywords:  Body mass index; C-peptide; Glucose; Insulin resistance

Mesh:

Substances:

Year:  2020        PMID: 34907766     DOI: 10.32725/jab.2020.018

Source DB:  PubMed          Journal:  J Appl Biomed        ISSN: 1214-021X            Impact factor:   1.797


  17 in total

Review 1.  C-peptide in the natural history of type 1 diabetes.

Authors:  Jerry P Palmer
Journal:  Diabetes Metab Res Rev       Date:  2009-05       Impact factor: 4.876

2.  When to consider a diagnosis of MODY at the presentation of diabetes: aetiology matters for correct management.

Authors:  Agata Juszczak; Rebecca Pryse; Andrew Schuman; Katharine R Owen
Journal:  Br J Gen Pract       Date:  2016-06       Impact factor: 5.386

3.  Glycaemic variability and hypoglycaemia are associated with C-peptide levels in insulin-treated type 2 diabetes.

Authors:  M B Christensen; P Gæde; E Hommel; A Gotfredsen; K Nørgaard
Journal:  Diabetes Metab       Date:  2019-02-21       Impact factor: 6.041

4.  Body adiposity and type 2 diabetes: increased risk with a high body fat percentage even having a normal BMI.

Authors:  Javier Gómez-Ambrosi; Camilo Silva; Juan C Galofré; Javier Escalada; Silvia Santos; María J Gil; Victor Valentí; Fernando Rotellar; Beatriz Ramírez; Javier Salvador; Gema Frühbeck
Journal:  Obesity (Silver Spring)       Date:  2011-03-10       Impact factor: 5.002

5.  C-peptide: A predictor of cardiovascular mortality in subjects with established atherosclerotic disease.

Authors:  Marina Cardellini; Alessio Farcomeni; Marta Ballanti; Monica Morelli; Francesca Davato; Iris Cardolini; Giulia Grappasonni; Stefano Rizza; Valeria Guglielmi; Ottavia Porzio; Chiara Pecchioli; Rossella Menghini; Arnaldo Ippoliti; Massimo Federici
Journal:  Diab Vasc Dis Res       Date:  2017-05-31       Impact factor: 3.291

6.  Correlation Among Hypoglycemia, Glycemic Variability, and C-Peptide Preservation After Alefacept Therapy in Patients with Type 1 Diabetes Mellitus: Analysis of Data from the Immune Tolerance Network T1DAL Trial.

Authors:  Ashley Pinckney; Mark R Rigby; Lynette Keyes-Elstein; Carol L Soppe; Gerald T Nepom; Mario R Ehlers
Journal:  Clin Ther       Date:  2016-05-18       Impact factor: 3.393

7.  Association between serum C-peptide as a risk factor for cardiovascular disease and high-density lipoprotein cholesterol levels in nondiabetic individuals.

Authors:  Ying Li; Yue Li; Lu Meng; LianShun Zheng
Journal:  PLoS One       Date:  2015-01-05       Impact factor: 3.240

8.  C-Peptide and cardiovascular risk factors among young adults in a southern Brazilian cohort.

Authors:  Romildo Luiz Monteiro Andrade; Denise P Gigante; Isabel Oliveira de Oliveira; Bernardo Lessa Horta
Journal:  BMC Endocr Disord       Date:  2018-11-06       Impact factor: 2.763

9.  Optimal Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) Cut-Offs: A Cross-Sectional Study in the Czech Population.

Authors:  Dagmar Horáková; Ladislav Štěpánek; Vladimír Janout; Jana Janoutová; Dalibor Pastucha; Helena Kollárová; Alena Petráková; Lubomír Štěpánek; Roman Husár; Karel Martiník
Journal:  Medicina (Kaunas)       Date:  2019-05-17       Impact factor: 2.430

10.  Biomarker potential of C-peptide for screening of insulin resistance in diabetic and non-diabetic individuals.

Authors:  Haseeb A Khan; Samia H Sobki; Aishah Ekhzaimy; Isra Khan; Mona A Almusawi
Journal:  Saudi J Biol Sci       Date:  2018-06-01       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.